<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9228">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05702450</url>
  </required_header>
  <id_info>
    <org_study_id>CM310-100002</org_study_id>
    <nct_id>NCT05702450</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310</brief_title>
  <official_title>A Randomized, Open, Parallel Phase I Clinical Study on the Comparison of Pharmacokinetics Characteristics of CM310 Recombinant Humanized Monoclonal Antibody Injection in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keymed Biosciences Co.Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keymed Biosciences Co.Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, open study to evaluate the pharmacokinetics, safety and&#xD;
      immunogenicity CM310 in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study includes screening and treatment and follow-up periods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 30, 2023</start_date>
  <completion_date type="Anticipated">March 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic: the maximum concentration (Cmax)</measure>
    <time_frame>up to 57 days</time_frame>
    <description>Concentration and exposure</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group P1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CM310, Subcutaneous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group P2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CM310, Subcutaneous, as the parallel control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CM310</intervention_name>
    <description>CM310 Recombinant Humanized Monoclonal Antibody Injection</description>
    <arm_group_label>Group P1</arm_group_label>
    <arm_group_label>Group P2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have the ability to understand the study.&#xD;
&#xD;
          -  Voluntarily participate in the study and sign the ICF.&#xD;
&#xD;
          -  18 years ≤ age ≤ 65 years, male and female.&#xD;
&#xD;
          -  Willing to take effective contraceptive measures during the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Plan to receive any major surgery during the study period.&#xD;
&#xD;
          -  With malignant tumors within 5 years before screening.&#xD;
&#xD;
          -  Positive results of alcohol breath test or urine drug abuse screening during screening&#xD;
             period.&#xD;
&#xD;
          -  Any reason that the investigator believes that will prevent the subject from&#xD;
             participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 12, 2023</study_first_submitted>
  <study_first_submitted_qc>January 25, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2023</study_first_posted>
  <last_update_submitted>January 25, 2023</last_update_submitted>
  <last_update_submitted_qc>January 25, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

